medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2018, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2018; 34 (4)

CAR T cells: progress that passes the advances in the treatment of malignant hemopathies

Martínez-Sánchez LM, Álvarez-Hernández LF, Roldán-Isaza M

Language: Spanish
References: 35
Page: 41-50
PDF size: 160.30 Kb.


ABSTRACT

Introduction: CAR T cells (antigenic chimeric receptor) are a new type of emergent treatment classified among adoptive cell transfer immunotherapies (ACT). This receptor will contribute to the detection of specific malignant antigens on the membrane of cancer cells and the destruction of these, which together with chemotherapy, allow an effective anti-tumor treatment.
Objective: to review the new therapies with CAR T cells in the common lymphomas, besides exposing the main complications and new therapeutic uses.
Methods: an exhaustive bibliographic review was carried out from December 2018 to June 2018 in databases such as Medline, Science Direct, Lilacs and Embase, with the search MeSH terms: lymphoma, immunotherapy, genetic engineering, T lymphocytes.
Conclusion: there are numerous applications of which this type of immunotherapy is a participant, currently proposes a therapeutic revolution in which not only include hematological malignancies, but also in solid tumors, is undoubtedly a feat of genetic engineering and medicine.


REFERENCES

  1. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62-8. doi: 10.1126/science.aaa4967.

  2. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. doi: 10.1056/NEJMoa1103849

  3. Pishko A, Nasta SD. The role of novel immunotherapies in non-Hodgkin lymphoma. Transl Cancer Res. 2017;6(1):93-103. doi: 10.21037/tcr.2017.01.08

  4. Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2017. doi: 10.1038/nrclinonc.2017.128.

  5. Schubert ML, Hoffmann JM, Dreger P, Müller-Tidow C, Schmitt M. Chimeric antigen receptor transduced T cells: Tuning up for the next generation. Int J Cancer. 2017 Nov 9. doi: 10.1002/ijc.31147.

  6. Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nature Rev Clin Oncol. 2016;13(6):370- 383. doi:10.1038/nrclinonc.2016.36.

  7. Song D-G, Ye Q, Poussin M, Chacon JA, Figini M, Powell DJ. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. J Hematol Oncol. 2016;9:56. doi:10.1186/s13045-016-0285-y.

  8. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388-98. doi:10.1158/2159-8290.CD-12-0548.

  9. Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183-1197. doi:10.15252/emmm.201607485.

  10. MacLeod DT, Antony J, Martin AJ, Moser RJ, Hekele A, Wetzel KJ, et al. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells. Mol Ther. 2017;25(4):949-961. doi:10.1016/j.ymthe.2017.02.005

  11. Levine BL, Miskin J, Wonnacott K, Keir C. Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Develop. 2017;4:92-101. doi:10.1016/j.omtm.2016.12.006.

  12. Tasian SK, Gardner RA. CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther Adv Hematol. 2015;6(5):228-241. doi:10.1177/2040620715588916.

  13. Varghese AM. Chimeric antigen receptor (CAR) T and other T cell strategies for pancreas adenocarcinoma. Chin Clin Oncol. 2017;6(6):66. doi:10.21037/cco.2017.09.04

  14. Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 2016;44(2):380-90.

  15. Abate-Daga D, Davila ML. CAR models: next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncol. 2016;3:16014-. doi:10.1038/mto.2016.14.

  16. Van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of secondgeneration chimeric antigen receptors. Nat Rev Drug Discov. 2015;14(7):499-509. doi:10.1038/nrd4597

  17. Guedan S, Posey AD, Shaw C, Wing A, Da T, Patel P.R, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight. 2018;3(1):e96976. doi:10.1172/jci.insight.96976.

  18. Avanzi MP, Brentjens RJ. Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma. J Natl Compr Canc Netw. 2017;15(11):1429-1437. doi: 10.6004/jnccn.2017.7045

  19. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. New Engl J Med. 2014;371(16):1507-1517. doi:10.1056/NEJMoa1407222.

  20. Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graftversus- host activity. Nat Med. 2017;23(2):242-249. doi: 10.1038/nm.4258

  21. Prasad V. Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol. 2018;15(1):11-12. doi:10.1038/nrclinonc.2017.156

  22. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017;377(26):2545-2554. doi: 10.1056/NEJMoa1708566.

  23. Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor - redirected lymphocytes. J Clin Invest. 2017;127(9):1-10. doi: 10.1172/JCI94306

  24. 24.Chen KH, Wada M, Pinz KG, Liu H, Lin KW, Jares A, et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia. 2017(10):2151-2160. doi: 10.1038/leu.2017.8.

  25. Makita S, Yoshimura K, Tobinai K. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci. 2017;108(6):1109-18.

  26. Badieyan ZS, Hoseini SS. Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells. Arch Immunol Ther Exp (Warsz). 2018. doi: 10.1007/s00005-018-0507-9.

  27. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine reléase syndrome. Blood. 2014, 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729.

  28. Paszkiewicz PJ, Fräßle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest. 2016;126(11):4262-4272. doi: 10.1172/JCI84813

  29. Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cellimmunotherapy: current understanding and future directions. J Gene Med. 2012;14(6):405-15. doi: 10.1002/jgm.2604.

  30. Albert S, Arndt C, Koristka S, Berndt N, Bergmann R, Feldmann A,et al. From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo. Oncotarget. 2018;9(39):25597-616. doi:10.18632/oncotarget.25390.

  31. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010; 70(22):9053- 61. doi: 10.1158/0008-5472.CAN-10-2880.

  32. Ma JSY, Kim JY, Kazane SA, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Nat Acad Sci USA. 2016;113(4):E450-E458. doi:10.1073/pnas.1524193113.

  33. Chen Y, E CY, Gong ZW, Liu S, Wang ZX, Yang YS, et al. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Hepatobiliary Pancreat Dis Int. 2018. pii: S1499-3872(18)30113-9. doi: 10.1016/j.hbpd.2018.05.005.

  34. Kim M, Pyo S, Kang CH, Lee CO, Lee HK, Choi SU, et al. Folate receptor 1(FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLoS One. 2018; 13(6):e0198347. doi: 10.1371/journal.pone.0198347.

  35. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106-15.




2020     |     www.medigraphic.com